Scholar Rock Holding Corporation Common Stock (SRRK) Stock Price

SRRKStock

$58.25+63.99%52W

Market Cap$7.09B

P/E—

PEG Ratio—

Div yield—

Beta0.58

SRRK Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)12.69%

Price vs S&P 500 (4W)14.83%

VGM Score43.85

Book Value / Share (Quarterly)$2.09

P/TBV (Annual)3.25x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-2.44

Price vs S&P 500 (YTD)20.16%

Net Profit Margin (TTM)-236.96%

EPS (TTM)$-3.30

10-Day Avg Trading Volume1.04M

EPS Excl Extra (TTM)$-3.30

EPS (Annual)$-2.47

ROI (Annual)-58.81%

Net Profit Margin (5Y Avg)-1236.36%

Cash / Share (Quarterly)$4.05

ROA (Last FY)-51.86%

EBITD / Share (TTM)$-3.27

ROE (5Y Avg)-60.37%

Operating Margin (TTM)-231.80%

Cash Flow / Share (Annual)$-2.77

P/B Ratio26.26x

P/B Ratio (Quarterly)25.97x

Net Income / Employee (Annual)$-852,200

EV / Revenue (TTM)135.80x

Net Interest Coverage (TTM)-809.50x

ROA (TTM)-86.60%

EPS Incl Extra (Annual)$-2.47

Current Ratio (Annual)6.95x

Quick Ratio (Quarterly)6.84x

3-Month Avg Trading Volume1.33M

52-Week Price Return63.99%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$2.98

P/S Ratio (Annual)200.79x

Asset Turnover (Annual)0.09x

52-Week High$58.75

Operating Margin (5Y Avg)-1238.26%

EPS Excl Extra (Annual)$-2.47

CapEx CAGR (5Y)-31.83%

Tangible BV CAGR (5Y)36.11%

26-Week Price Return23.94%

Quick Ratio (Annual)6.68x

13-Week Price Return21.96%

Total Debt / Equity (Annual)0.41x

Current Ratio (Quarterly)7.02x

Enterprise Value$6.42B

Asset Turnover (TTM)0.16x

Book Value / Share Growth (5Y)-21.57%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-405.24%

Cash / Share (Annual)$3.39

3-Month Return Std Dev48.18%

Net Income / Employee (TTM)$-1,404,400

ROE (Last FY)-66.81%

EPS Basic Excl Extra (Annual)$-2.47

Receivables Turnover (TTM)1.23x

Total Debt / Equity (Quarterly)0.77x

EPS Incl Extra (TTM)$-3.30

ROI (TTM)-100.69%

P/S Ratio (TTM)140.89x

Pretax Margin (5Y Avg)-1236.36%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$5.04

Price vs S&P 500 (52W)45.68%

Year-to-Date Return32.12%

5-Day Price Return6.36%

EPS Normalized (Annual)$-2.47

ROA (5Y Avg)-41.66%

Net Profit Margin (Annual)-405.24%

Month-to-Date Return23.06%

Cash Flow / Share (TTM)$-1.95

EBITD / Share (Annual)$-2.51

Operating Margin (Annual)-404.85%

LT Debt / Equity (Annual)0.41x

ROI (5Y Avg)-50.42%

LT Debt / Equity (Quarterly)0.77x

EPS Basic Excl Extra (TTM)$-3.30

P/TBV (Quarterly)5.05x

P/B Ratio (Annual)18.30x

Pretax Margin (TTM)-236.96%

Book Value / Share (Annual)$2.26

Price vs S&P 500 (13W)19.17%

Beta0.58x

P/FCF (Annual)288.74x

Revenue / Share (TTM)$0.00

ROE (TTM)-159.12%

52-Week Low$27.07

vGradeF

mGradeB

vgmGradeC

SRRK Earnings Surprise History

Q2 25-0.98est. -0.67

Q3 25-0.90est. -0.84

Q4 25-0.88est. -0.88

Q1 26-0.83est. -0.78

Q2 26-0.84est. -0.84

SRRK Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.35

4.33

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	C	$14.56

About Scholar Rock Holding Corporation Common Stock

Scholar Rock is a biopharmaceutical company developing treatments for rare neuromuscular diseases, with a focus on Spinal Muscular Atrophy. Its lead candidate, apitegromab, is in clinical development with both intravenous and subcutaneous formulations. The company's pipeline also includes SRK-439, a myostatin inhibitor in development for rare neuromuscular indications.